高通量血液透析联合血液灌流对维持性血液透析患者免疫功能、钙磷代谢及营养状况的影响分析OA
Analysis on the Impact of High-Flux Hemodialysis Combined with Hemoper-fusion on Immune Function,Calcium-Phosphorus Metabolism and Nutritional Status in Patients with Maintenance Hemodialysis
目的 探讨高通量血液透析(HFHD)联合血液灌流(HP)对维持性血液透析(MHD)患者免疫功能、钙磷代谢及营养状况的影响.方法 选取2025年1月至2025年9月于东台市中医院接受MHD治疗的96例终末期肾病患者,依据随机数表法分为两组,各48例.对照组采用单纯HFHD治疗,观察组采用HFHD联合HP治疗,均连续治疗3个月.比较两组治疗前后的免疫功能指标(IgG、IgA、IgM、IgE)、钙磷代谢指标(PTH、血钙、血磷)、营养指标(Alb、PA、TRF)及并发症发生情况.结果 治疗3个月后,两组的免疫功能指标、钙磷代谢指标、营养指标均较治疗前明显改善(P＜0.05).治疗3个月后,观察组的IgG、IgA、IgM 水平分别为(10.56±1.32)g/L、(2.34±0.45)g/L、(1.32±0.28)g/L,均高于对照组的(8.34±1.25)g/L、(1.89±0.41)g/L、(1.05±0.25)g/L;观察组的 IgE 水平为(89.32±18.56)IU/mL,低于对照组的(105.67±20.34)IU/mL(P＜0.05).治疗 3 个月后,观察组的 PTH、血钙、血磷水平分别为(356.78±98.45)pg/mL、(2.23±0.21)mmol/L、(1.78±0.32)mmol/L,均优于对照组的(489.34±105.67)pg/mL、(2.05±0.23)mmol/L、(2.23±0.35)mmol/L(P＜0.05).治疗 3 个月后,观察组的 Alb、PA、TRF 水平分别为(38.78±3.67)g/L、(245.67±28.91)mg/L、(2.89±0.41)g/L,均高于对照组的(35.45±3.52)g/L、(212.34±27.65)mg/L、(2.56±0.39)g/L(P＜0.05).观察组的并发症总发生率为 12.50％,低于对照组的 29.17％(P＜0.05).结论 HFHD联合HP可显著改善MHD患者的免疫功能、钙磷代谢及营养状况,减少并发症的发生,临床应用价值显著.
Objective To investigate the impact of high-flux hemodialysis(HFHD)combined with hemoperfusion(HP)on immune function,calcium-phosphorus metabolism and nutritional status in patients with maintenance hemodialysis(MHD).Methods A total of 96 patients with end-stage renal disease who received MHD in Dongtai Hospital of Chinese Medicine from January 2025 to September 2025 were enrolled and divided into two groups using a random number table,with 48 cases in each group.The control group was treated with HFHD alone,while the observation group was treated with HFHD combined with HP.Both groups were treated continuously for 3 months.The immune function indicators(IgG,IgA,IgM,IgE),calcium-phosphorus metabolism indicators(PTH,serum calcium,serum phosphorus),nutritional indicators(Alb,PA,TRF)before and after treatment,and the occurrence of complications were compared between the two groups.Results After 3 months of treatment,the immune function indicators,calcium-phosphorus metabolism indicators and nutritional indicators in both groups were significantly improved compared with those before treatment(P＜0.05).After 3 months of treatment,the IgG,IgA,and IgM levels of the observation group were(10.56±1.32)g/L,(2.34±0.45)g/L and(1.32±0.28)g/L respectively,higher than(8.34±1.25)g/L,(1.89±0.41)g/L and(1.05±0.25)g/L of the control group;the IgE level of the observation group was(89.32±18.56)IU/mL,lower than(105.67±20.34)IU/mL of the control group(P＜0.05).After 3 months of treatment,the PTH,blood calcium,and blood phosphorus levels of the observation group were(356.78±98.45)pg/mL,(2.23±0.21)mmol/L,and(1.78±0.32)mmol/L,respectively,better than(489.34±105.67)pg/mL,(2.05±0.23)mmol/L,and(2.23±0.35)mmol/L of the control group(P＜0.05).After 3 months of treatment,the Alb,PA,and TRF levels of the observation group were(38.78±3.67)g/L,(245.67±28.91)mg/L and(2.89±0.41)g/L,respectively,higher than(35.45±3.52)g/L,(212.34±27.65)mg/L and(2.56±0.39)g/L of the control group(P＜0.05).The overall incidence of complications in the observation group was 12.50％,lower than 29.17％in the control group(P＜0.05).Conclusions HFHD combined with HP can significantly improve immune function,calcium-phosphorus metabolism and nutritional status,and reduce the occurrence of complications in patients with MHD,which possesses significant clinical application value.
何汝明;沈小燕
东台市中医院肾病科,江苏东台 224000东台市中医院肾病科,江苏东台 224000
医药卫生
高通量血液透析血液灌流维持性血液透析免疫功能钙磷代谢营养状况
High-flux hemodialysisHemoperfusionMaintenance hemodialysisImmune functionCalcium-phosphorus metabolismNutritional status
《临床医学工程》 2026 (9)
1034-1038,5
东台市医疗卫生领域科技计划项目(项目编号:DTYW2024018)
评论